Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EICESS 92: Chemotherapy and Radiotherapy in Ewing's Sarcoma
NCT00002516Phase 3Unknown
- Sponsor
- Universitätsklinikum Münster
- Start
- Jul 1992
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of etoposide and cyclophosphamide in Ewing sarcoma and Peripheral Primitive Neuroectodermal Tumor (pPNET) (4 arms), sponsored by Universitätsklinikum Münster. Primary endpoint: Event-Free Survival at 3 years. Status: unknown.
02
Drugs
etoposidecyclophosphamide
03
Conditions
Ewing sarcomaPeripheral Primitive Neuroectodermal Tumor (pPNET)
Beyond the preview
Go deeper on NCT00002516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002516.